Max Kurlbaum
Overview
Explore the profile of Max Kurlbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit G, Gesierich A, Schilling B, et al.
J Pharm Biomed Anal
. 2023 Feb;
228:115311.
PMID: 36841066
Volumetric absorptive microsampling (VAMS) has emerged as a minimally invasive alternative to conventional sampling. However, the applicability of VAMS must be investigated clinically. Therefore, the feasibility of at-home sampling was...
12.
Balonov I, Kurlbaum M, Koschker A, Stier C, Fassnacht M, Dischinger U
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768676
Although bariatric surgery is known to change the metabolome, it is unclear if this is specific for the intervention or a consequence of the induced bodyweight loss. As the weight...
13.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit G, Zimmermann S, Kurlbaum M, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559050
Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD...
14.
Isberner N, Gesierich A, Balakirouchenane D, Schilling B, Aghai-Trommeschlaeger F, Zimmermann S, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230489
Patients treated with dabrafenib and trametinib for BRAF-mutant melanoma often experience dose reductions and treatment discontinuations. Current knowledge about the associations between patient characteristics, adverse events (AE), and exposure is...
15.
Vogg N, Muller T, Floren A, Dandekar T, Scherf-Clavel O, Fassnacht M, et al.
J Mass Spectrom Adv Clin Lab
. 2022 Aug;
25:44-52.
PMID: 35910411
Introduction: Preoperative diagnostic workup of adrenal tumors is based on imaging and hormone analyses, but charged with uncertainties. Steroid profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 24-h urine...
16.
Aghai-Trommeschlaeger F, Zimmermann S, Gesierich A, Kalogirou C, Goebeler M, Jung P, et al.
Clin Biochem
. 2022 Apr;
105-106:35-43.
PMID: 35483452
Objective: Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a highly selective and sensitive method for the quantification of kinase inhibitors, yet not widely available in clinical routine for therapeutic drug...
17.
Eisenhofer G, Kurlbaum M, Peitzsch M, Constantinescu G, Remde H, Schulze M, et al.
J Clin Endocrinol Metab
. 2021 Dec;
107(5):e2027-e2036.
PMID: 34963138
Context: Diagnosis of primary aldosteronism (PA) for many patients depends on positive results for the saline infusion test (SIT). Plasma aldosterone is often measured by immunoassays, which can return inaccurate...
18.
Ruggiero C, Altieri B, Arnold E, Siqueiros-Marquez L, Doghman-Bouguerra M, Detomas M, et al.
Clin Transl Med
. 2021 Nov;
11(11):e630.
PMID: 34841740
No abstract available.
19.
Marz J, Kurlbaum M, Roche-Lancaster O, Deutschbein T, Peitzsch M, Prehn C, et al.
Front Endocrinol (Lausanne)
. 2021 Sep;
12:722656.
PMID: 34557163
Context: Pheochromocytomas and paragangliomas (PPGL) cause catecholamine excess leading to a characteristic clinical phenotype. Intra-individual changes at metabolome level have been described after surgical PPGL removal. The value of metabolomics...
20.
Isberner N, Kraus S, Grigoleit G, Aghai F, Kurlbaum M, Zimmermann S, et al.
Cancer Chemother Pharmacol
. 2021 Sep;
88(6):973-983.
PMID: 34505930
Purpose: Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and...